

Vincent van Pesch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8562953/publications.pdf>

Version: 2024-02-01

142
papers

6,320
citations

76294

40
h-index

76872

74
g-index

152
all docs

152
docs citations

152
times ranked

7209
citing authors

#	ARTICLE	IF	CITATIONS
1	A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. <i>Neurology</i> , 2009, 73, 1914-1922.	1.5	653
2	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 175.	3.8	336
3	Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016, 139, 2395-2405.	3.7	281
4	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 307-316.	4.9	219
5	Characterization of the Murine Alpha Interferon Gene Family. <i>Journal of Virology</i> , 2004, 78, 8219-8228.	1.5	187
6	Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. <i>PLoS ONE</i> , 2012, 7, e48078.	1.1	166
7	Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , 2015, 138, 3287-3298.	3.7	162
8	A basic overview of multiple sclerosis immunopathology. <i>European Journal of Neurology</i> , 2015, 22, 3-13.	1.7	158
9	Predictors of long-term disability accrual in relapse-onset multiple sclerosis. <i>Annals of Neurology</i> , 2016, 80, 89-100.	2.8	158
10	Immune-mediated neurological syndromes in SARS-CoV-2-infected patients. <i>Journal of Neurology</i> , 2021, 268, 751-757.	1.8	154
11	Predictors and dynamics of postpartum relapses in women with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 739-746.	1.4	148
12	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. <i>Brain</i> , 2013, 136, 3609-3617.	3.7	140
13	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 271-281.	4.9	134
14	Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. <i>PLoS ONE</i> , 2015, 10, e0122686.	1.1	122
15	The Leader Protein of Theiler's Virus Inhibits Immediate-Early Alpha/Beta Interferon Production. <i>Journal of Virology</i> , 2001, 75, 7811-7817.	1.5	117
16	The Leader Protein of Theiler's Virus Interferes with Nucleocytoplasmic Trafficking of Cellular Proteins. <i>Journal of Virology</i> , 2004, 78, 4357-4362.	1.5	106
17	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 405.	4.5	100
18	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017, 140, 2426-2443.	3.7	94

#	ARTICLE	IF	CITATIONS
19	Paramagnetic Rim Lesions are Specific to Multiple Sclerosis: An International Multicenter 3T MRI Study. <i>Annals of Neurology</i> , 2020, 88, 1034-1042.	2.8	89
20	Voxel-based lesion-symptom mapping of stroke lesions underlying somatosensory deficits. <i>NeuroImage: Clinical</i> , 2016, 10, 257-266.	1.4	88
21	Neurofilament ELISA validation. <i>Journal of Immunological Methods</i> , 2010, 352, 23-31.	0.6	86
22	Risk of relapse phenotype recurrence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1511-1522.	1.4	73
23	Polymerase chain reaction analysis and oligoclonal antibody in the cerebrospinal fluid from 34 patients with varicella-zoster virus infection of the nervous system. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 938-942.	0.9	71
24	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 458-468.	0.9	71
25	Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. <i>Annals of Neurology</i> , 2014, 76, 880-890.	2.8	67
26	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1343-1349.	0.9	63
27	Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM. <i>Journal of Proteomics</i> , 2013, 78, 312-325.	1.2	58
28	The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. <i>Multiple Sclerosis Journal</i> , 2012, 18, 974-982.	1.4	56
29	International consensus on quality standards for brain health-focused care in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1809-1818.	1.4	55
30	Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. <i>Brain</i> , 2015, 138, 632-643.	3.7	54
31	Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e543-e553.	1.5	54
32	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , 2021, 96, e783-e797.	1.5	54
33	Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. <i>Multiple Sclerosis International</i> , 2011, 2011, 1-9.	0.4	52
34	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 912-923.	1.4	52
35	Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 79-90.	1.4	52
36	Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. <i>Journal of Neurology</i> , 2005, 252, 1217-1222.	1.8	51

#	ARTICLE	IF	CITATIONS
37	Concomitant Analysis of Arterial, Venous, and CSF Flows using Phase-Contrast MRI: A Quantitative Comparison Between MS Patients and Healthy Controls. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 1314-1321.	2.4	51
38	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 196-203.	0.9	49
39	Fingolimod Increases CD39-Expressing Regulatory T Cells in Multiple Sclerosis Patients. <i>PLoS ONE</i> , 2014, 9, e113025.	1.1	45
40	Predictors of disability worsening in clinically isolated syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 479-491.	1.7	43
41	Characterization of Interferon- γ 13, a Novel Constitutive Murine Interferon- γ Subtype. <i>Journal of Biological Chemistry</i> , 2003, 278, 46321-46328.	1.6	41
42	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. <i>Neurology</i> , 2021, 96, .	1.5	41
43	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1031-1044.	1.4	39
44	Extracellular vesicles for the treatment of central nervous system diseases. <i>Advanced Drug Delivery Reviews</i> , 2021, 174, 535-552.	6.6	39
45	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. <i>Neurology</i> , 2017, 89, 1050-1059.	1.5	38
46	The Kurtzke EDSS rank stability increases 4â€¦years after the onset of multiple sclerosis: results from the MSBase Registry. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 305-310.	0.9	37
47	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 642-652.	1.4	37
48	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsingâ€“remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1159-1171.	1.4	36
49	Increasing age at disability milestones among MS patients in the MSBase Registry. <i>Journal of the Neurological Sciences</i> , 2012, 318, 94-99.	0.3	35
50	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 235-243.	0.9	35
51	Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. <i>PLoS ONE</i> , 2012, 7, e38661.	1.1	35
52	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 520-532.	1.4	34
53	Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid A β 242 and T-Tau assays for Alzheimerâ€™s disease diagnosis. <i>Journal of Neurology</i> , 2019, 266, 2304-2311.	1.8	34
54	IL-22, GM-CSF and IL-17 in peripheral CD4+ T cell subpopulations during multiple sclerosis relapses and remission. Impact of corticosteroid therapy. <i>PLoS ONE</i> , 2017, 12, e0173780.	1.1	33

#	ARTICLE	IF	CITATIONS
55	A Role for GDNF and Soluble APP as Biomarkers of Amyotrophic Lateral Sclerosis Pathophysiology. <i>Frontiers in Neurology</i> , 2018, 9, 384.	1.1	33
56	Quantitative proteomics suggests decrease in the secretograninâ€1 cerebrospinal fluid levels during the disease course of multiple sclerosis. <i>Proteomics</i> , 2015, 15, 3361-3369.	1.3	32
57	Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , 2020, 143, 1400-1413.	3.7	32
58	Corticosteroids in the management of acute multiple sclerosis exacerbations. <i>Acta Neurologica Belgica</i> , 2017, 117, 623-633.	0.5	31
59	Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 266-276.	1.4	30
60	Timed Up-and-Go and 2-Minute Walk Test in patients with multiple sclerosis with mild disability: reliability, responsiveness and link with perceived fatigue. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2019, 55, 450-455.	1.1	29
61	Early disturbances in multimodal evoked potentials as a prognostic factor for long-term disability in relapsing-relapsing multiple sclerosis patients. <i>Clinical Neurophysiology</i> , 2017, 128, 561-569.	0.7	27
62	Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis. <i>Patient Related Outcome Measures</i> , 2018, Volume 9, 1-10.	0.7	27
63	Upregulation of IL-17, but not of IL-9, in circulating cells of CIS and relapsing MS patients. Impact of corticosteroid therapy on the cytokine network. <i>Journal of Neuroimmunology</i> , 2012, 243, 73-80.	1.1	26
64	Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e63480.	1.1	26
65	Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis. <i>Proteomics</i> , 2016, 16, 1154-1165.	1.3	26
66	Susac-Like Syndrome in a Chronic Cocaine Abuser: Could Levamisole Play a Role?. <i>Journal of Medical Toxicology</i> , 2015, 11, 124-128.	0.8	25
67	Decrease of blood anti-Î±1,3 Galactose Abs levels in multiple sclerosis (MS) and clinically isolated syndrome (CIS) patients. <i>Clinical Immunology</i> , 2017, 180, 128-135.	1.4	25
68	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756.	3.7	24
69	Anti-N-Methyl-D-Aspartate Receptor Encephalitis with Favorable Outcome Despite Prolonged Status Epilepticus. <i>Neurocritical Care</i> , 2013, 18, 89-92.	1.2	23
70	CSF microRNAs discriminate MS activity and share similarity to other neuroinflammatory disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	23
71	Prognostic indicators and outcomes of hospitalised COVID-19 patients with neurological disease: An individual patient data meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0263595.	1.1	22
72	Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program. <i>Acta Neurologica Belgica</i> , 2014, 114, 167-178.	0.5	21

#	ARTICLE	IF	CITATIONS
73	Regulation of Treg-associated CD39 in multiple sclerosis and effects of corticotherapy during relapse. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1533-1545.	1.4	21
74	Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 1398.	4.5	21
75	Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 208, 106180.	2.6	21
76	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2018, 75, 1407.	4.5	20
77	Effectiveness and safety of natalizumab in real-world clinical practice: Review of observational studies. <i>Clinical Neurology and Neurosurgery</i> , 2016, 149, 55-63.	0.6	19
78	Effects of Fampridine in People with Multiple Sclerosis: A Systematic Review and Meta-analysis. <i>CNS Drugs</i> , 2019, 33, 1087-1099.	2.7	19
79	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1346-1357.	1.4	18
80	Fatigue and physical fitness of mildly disabled persons with multiple sclerosis: a cross-sectional study. <i>International Journal of Rehabilitation Research</i> , 2017, 40, 268-274.	0.7	17
81	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 11-19.	0.9	17
82	The central vein sign in multiple sclerosis patients with vascular comorbidities. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1057-1065.	1.4	16
83	Molecular Mechanisms of Immunosenescence and Inflammaging: Relevance to the Immunopathogenesis and Treatment of Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 811518.	1.1	16
84	Free Kappa light chains in neuroinflammatory disorders: Complement rather than substitute?. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 352-358.	1.0	13
85	Partly reversible central auditory dysfunction induced by cerebral vasospasm after subarachnoid hemorrhage. <i>Journal of Neurosurgery</i> , 2013, 119, 1125-1128.	0.9	12
86	Auto-immune hepatitis in a patient with multiple sclerosis treated with alemtuzumab. <i>Acta Neurologica Belgica</i> , 2018, 118, 331-333.	0.5	12
87	Prophylactic treatment against GM-CSF, but not IL-17, abolishes relapses in a chronic murine model of multiple sclerosis. <i>European Journal of Immunology</i> , 2018, 48, 1883-1891.	1.6	12
88	Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. <i>European Journal of Neurology</i> , 2019, 26, 363-370.	1.7	12
89	Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis. <i>Neurology</i> , 2022, 98, .	1.5	12
90	Novel cerebrospinal fluid and serum autoantibody targets for clinically isolated syndrome. <i>Journal of Neurochemistry</i> , 2012, 123, 568-577.	2.1	11

#	ARTICLE	IF	CITATIONS
91	Anti-SPAG 16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index. <i>European Journal of Neurology</i> , 2016, 23, 722-728.	1.7	11
92	Premotor dorsal white matter integrity for the prediction of upper limb motor impairment after stroke. <i>Scientific Reports</i> , 2019, 9, 19712.	1.6	11
93	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 755-766.	1.4	11
94	Telecommunication and rehabilitation for patients with multiple sclerosis: access and willingness to use. A cross-sectional study. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2020, 56, 403-411.	1.1	11
95	Fluctuations of MS births and UV-light exposure. <i>Acta Neurologica Scandinavica</i> , 2013, 127, 301-308.	1.0	10
96	Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus. <i>Acta Neurologica Belgica</i> , 2018, 118, 7-11.	0.5	10
97	Clinical Significance of Antiproteinase 3 Antibody Positivity in cANCA-Positive Patients. <i>Clinical Rheumatology</i> , 1999, 18, 279-282.	1.0	9
98	Historical changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: a multicenter study. <i>Journal of Neurology</i> , 2013, 260, 1258-1262.	1.8	9
99	New-Onset Refractory Status Epilepticus: More Investigations, More Questions. <i>Case Reports in Neurology</i> , 2016, 8, 127-133.	0.3	9
100	Early relapse with tumefactive MS lesion upon initiation of fingolimod therapy. <i>Acta Neurologica Belgica</i> , 2016, 116, 95-97.	0.5	9
101	Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. <i>Journal of the Neurological Sciences</i> , 2021, 430, 118067.	0.3	9
102	Clinical, electrophysiological and brain imaging features during recurrent ictal cortical blindness associated with chronic liver failure. <i>Acta Neurologica Belgica</i> , 2006, 106, 215-8.	0.5	9
103	Silent lesions on MRI imaging – Shifting goal posts for treatment decisions in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1569-1577.	1.4	8
104	Mechanism of Cellular Formation and In Vivo Seeding Effects of Hexameric β -Amyloid Assemblies. <i>Molecular Neurobiology</i> , 2021, 58, 6647-6669.	1.9	8
105	Short commentary on – a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking™. <i>Multiple Sclerosis Journal</i> , 2010, 16, 129-132.	1.4	7
106	Ventricular arrhythmia in a male MS patient on fingolimod. <i>Acta Neurologica Belgica</i> , 2015, 115, 77-79.	0.5	7
107	Needs and Experiences of Children and Adolescents with Pediatric Multiple Sclerosis and Their Caregivers: A Systematic Review. <i>Children</i> , 2021, 8, 445.	0.6	7
108	A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis. <i>Acta Neurologica Belgica</i> , 2018, 118, 161-168.	0.5	6

#	ARTICLE	IF	CITATIONS
109	Treatment response score to glatiramer acetate or interferon beta-1a. <i>Neurology</i> , 2020, 96, 10.1212/WNL.0000000000010991.	1.5	6
110	Recurrent Miller Fisher Syndrome with Vestibular Involvement. <i>European Neurology</i> , 2011, 66, 210-214.	0.6	5
111	Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2015, 1, 205521731560019.	0.5	5
112	Reversible Akinetic Mutism after Aneurysmal Subarachnoid Haemorrhage in the Territory of the Anterior Cerebral Artery without Permanent Ischaemic Damage to Anterior Cingulate Gyri. <i>Case Reports in Neurological Medicine</i> , 2016, 2016, 1-6.	0.3	5
113	Which treatment strategies for polyrefractory Neuro-Behçet disease?. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 203-205.	0.9	5
114	MOG antibody-related isolated rhombencephalitis revealed by paroxysmal dysarthria. <i>Journal of the Neurological Sciences</i> , 2019, 405, 116417.	0.3	4
115	Acute Susac Syndrome in a Recent User of Adulterated Cocaine: Levamisole as a Triggering Factor?. <i>Case Reports in Neurology</i> , 2020, 12, 78-83.	0.3	4
116	Paraneoplastic encephalomyelitis revealing burned-out seminoma. <i>Acta Neurologica Belgica</i> , 2021, 121, 767-769.	0.5	4
117	Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking. <i>Laboratoriums Medizin</i> , 2010, 34, 1-12.	0.1	3
118	Prolonged Toxic Encephalopathy following Accidental 4-Aminopyridine Overdose. <i>Case Reports in Neurological Medicine</i> , 2014, 2014, 1-4.	0.3	3
119	Herpes simplex encephalitis relapse associated with positive N-methyl-d-aspartate receptor antibodies. <i>Acta Neurologica Belgica</i> , 2018, 118, 533-535.	0.5	3
120	Anti-Ma2/Ta paraneoplastic rhombencephalitis in a patient with lung cancer responsive to anti-PD1 therapy. <i>Acta Neurologica Belgica</i> , 2020, 120, 451-452.	0.5	3
121	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1838-1851.	1.4	3
122	Cutaneous diseases related to a hyperactive T-cell response in ocrelizumab-treated multiple sclerosis patients. <i>Journal of Neurology</i> , 2021, 268, 4376-4378.	1.8	3
123	Comment on "Paraneoplastic encephalomyelitis revealing burned-out seminoma" confirmed case of anti-Kelch-like protein-11 encephalomyelitis. <i>Acta Neurologica Belgica</i> , 2021, , 1.	0.5	3
124	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. <i>Pharmacoeconomics</i> , 2022, 40, 323-339.	1.7	3
125	EXPOSURE TO INTERFERON-Î² THERAPY IN EARLY PREGNANCY: A LITERATURE REVIEW OF PREGNANCY OUTCOMES IN WOMEN WITH MULTIPLE SCLEROSIS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, A17.2-A17.	0.9	2
126	Improvement in progressive multifocal leukoencephalopathy after pembrolizumab-induced immune reconstruction inflammatory syndrome in a patient with follicular lymphoma. <i>EJHaem</i> , 2020, 1, 585-588.	0.4	2

#	ARTICLE	IF	CITATIONS
127	Simultaneous bilateral optic neuropathy and myelitis revealing paraneoplastic neurological syndrome associated with multiple onconeural antibodies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102789.	0.9	2
128	Effects of prolonged-release fampridine on multiple sclerosis-related gait impairments. A crossover, double-blinded, placebo-controlled study. <i>Clinical Biomechanics</i> , 2021, 86, 105382.	0.5	2
129	Transient perioperative visual loss after an elective neurosurgical procedure. <i>Acta Anaesthesiologica Belgica</i> , 2013, 64, 109-13.	0.0	2
130	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. <i>Multiple Sclerosis Journal</i> , 2022, , 135245852210845.	1.4	2
131	Idiopathic limbic encephalitis associated with antibodies to glutamic acid decarboxylase. <i>Acta Neurologica Belgica</i> , 2015, 115, 165-167.	0.5	1
132	Crampâ€fasciculation syndrome associated with monofocal motor neuropathy. <i>Muscle and Nerve</i> , 2017, 56, 828-832.	1.0	1
133	Response to correspondence: â€œInterferon alpha might be an alternative therapeutic choice for refractory neuro-Behâ€Set's diseaseâ€•â€“ Authors reply. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 29, 154.	0.9	1
134	Intravenous immunoglobulin-induced aseptic meningitis in a patient with Miller Fisher syndrome. <i>Acta Neurologica Belgica</i> , 2020, 120, 1015-1016.	0.5	1
135	Clinical usefulness of the CSF β -amyloid $A\beta$ 1-42/ $A\beta$ 1-40 ratio for Alzheimerâ€™s disease diagnosis: a retrospective study in a Belgian academic hospital. <i>Acta Neurologica Belgica</i> , 2022, 122, 245-247.	0.5	1
136	Confirmed disability progression as a marker of permanent disability in multiple sclerosis. <i>European Journal of Neurology</i> , 2022, , .	1.7	1
137	Encâ€phalopathie Ã complexes triphasiques et syndrome de Guillain-BarrÃ© retardÃ© lors dâ€™une intoxication aiguÃ© par un herbicide Ã chlorophÃ©noxy Ã». <i>Annales Francaises De Medecine D'Urgence</i> , 2011, 1, 349-351.	0.0	0
138	Vitamin D supplementation in multiple sclerosis patients in 2012: hype or reality as an adjunctive therapy?. <i>Acta Neurologica Belgica</i> , 2012, 112, 325-325.	0.5	0
139	Brainstem somatosensory and auditory evoked responses in central pontine myelinolysis. <i>Acta Neurologica Belgica</i> , 2014, 114, 225-226.	0.5	0
140	Are simplified indices of exercise tolerance well correlated to VO2peak among patients with multiple sclerosis: A case-control study. <i>Annals of Physical and Rehabilitation Medicine</i> , 2018, 61, e45.	1.1	0
141	Bingâ€™Neel syndrome hidden by multiple sclerosis, a challenging overlay of diseases. <i>Acta Neurologica Belgica</i> , 2022, 122, 227-229.	0.5	0
142	O36â€... Ocrelizumab real-world effectiveness in patients with relapsing and primary progressive multiple sclerosis: MuSicalE baseline data. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A24.3-A25.	0.9	0